docs2imageIcon
dark theme
hamburger menu
Chart & Data
Search a stock ticker below to get started.
Search
ATNF - $2.54
180 Life Sciences Corp.
1day
1w
1m
3m
6m
1yr
5yr
Yearly revenue growth: 0.0%
Yearly profit growth: 0.0%
Balance sheet (assets & liabs)
Institutional holders
Owner Share amount
The Vanguard Group, Inc. 928,530
Susquehanna Financial Group LLLP 528,427
BlackRock Fund Advisors 230,491
Geode Capital Management LLC 128,723
Citadel Advisors LLC 102,040
Group One Trading LP 82,762
Morgan Stanley Smith Barney LLC (... 82,126
Boothbay Fund Management LLC 61,576
Jane Street Capital LLC 58,856
Morgan Stanley & Co. LLC 53,029
180 Life Sciences Corp.
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Shareholder breakdown
general public
institutions
insiders